Patents by Inventor Robert K. Schultz
Robert K. Schultz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210380761Abstract: The present application provides polymer materials having the desired properties for implantation into a human or animal body, in particular, biocompatibility, biodegradability, radiopacity and mechanical properties. Methods of making such polymer materials, compositions or devices comprising such polymer materials, and uses of such polymer materials, compositions and devices are also disclosed.Type: ApplicationFiled: August 7, 2019Publication date: December 9, 2021Inventors: Robert K. Schultz, Lioubov Kabalnova, Donald K. Brandom, Jessica Earley, Ernest G. Baluca, Durgadas Bolikal
-
Publication number: 20180008753Abstract: Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer. In certain configurations, the heavy atoms are present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes an HACSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. A polymeric material that includes a SCC polymer may also be fabricated into other medical devices, such as stents.Type: ApplicationFiled: September 22, 2017Publication date: January 11, 2018Inventors: Donald K. Brandom, James E. McGrath, Joan Zeltinger, Eric V. Schmid, Robert K. Schultz
-
Patent number: 9782523Abstract: Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer. In certain configurations, the heavy atoms are present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes an HACSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. A polymeric material that includes a SCC polymer may also be fabricated into other medical devices, such as stents.Type: GrantFiled: May 5, 2011Date of Patent: October 10, 2017Assignee: Reva Medical, Inc.Inventors: Donald K. Brandom, James E. McGrath, Joan Zeltinger, Eric V. Schmid, Robert K. Schultz
-
Patent number: 8703113Abstract: Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer. In certain configurations, the heavy atoms are present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes an HACSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. A polymeric material that includes a SCC polymer may also be fabricated into other medical devices, such as stents.Type: GrantFiled: January 18, 2006Date of Patent: April 22, 2014Assignee: REVA Medical Inc.Inventors: Donald K. Brandom, James E. McGrath, Joan Zeltinger, Eric V. Schmid, Robert K. Schultz
-
Patent number: 8236340Abstract: The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent.Type: GrantFiled: June 10, 2008Date of Patent: August 7, 2012Assignee: REVA Medical, Inc.Inventor: Robert K Schultz
-
Publication number: 20110213456Abstract: Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer. In certain configurations, the heavy atoms are present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes an HACSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. A polymeric material that includes a SCC polymer may also be fabricated into other medical devices, such as stents.Type: ApplicationFiled: May 5, 2011Publication date: September 1, 2011Applicant: REVA Medical, Inc.Inventors: Donald K. Brandom, James E. McGrath, Joan Zeltinger, Eric V. Schmid, Robert K. Schultz
-
Publication number: 20080274159Abstract: The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent.Type: ApplicationFiled: June 10, 2008Publication date: November 6, 2008Applicant: REVA MEDICAL, INC.Inventor: Robert K. Schultz
-
Patent number: 7105152Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.Type: GrantFiled: May 31, 1995Date of Patent: September 12, 2006Assignee: 3M Innovative Properties CompanyInventors: Robert K. Schultz, David W. Schultz, Robert A. Moris
-
Patent number: 7101534Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.Type: GrantFiled: May 31, 1995Date of Patent: September 5, 2006Assignee: 3M Innovative Properties CompanyInventors: Robert K. Schultz, David W. Schultz, Robert A. Moris
-
Publication number: 20040224003Abstract: The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent.Type: ApplicationFiled: February 6, 2004Publication date: November 11, 2004Inventor: Robert K. Schultz
-
Publication number: 20040197273Abstract: A pharmaceutical suspension aerosol formulation containing HFA-227 as a propellant.Type: ApplicationFiled: April 9, 2004Publication date: October 7, 2004Applicant: 3M COMPANYInventors: Robert K. Schultz, David W. Schultz, Martin J. Oliver, Robert A. Moris, Philip A. Jinks
-
Patent number: 6743413Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.Type: GrantFiled: May 31, 1995Date of Patent: June 1, 2004Assignee: 3M CompanyInventors: Robert K. Schultz, David W. Schultz, Martin J. Oliver, Robert A. Moris, Philip A. Jinks
-
Publication number: 20040013611Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.Type: ApplicationFiled: July 9, 2003Publication date: January 22, 2004Applicant: Minnesota Mining and Manufacturing Company, now 3M CompanyInventors: Robert K. Schultz, David W. Schultz, Martin J. Oliver, Robert A. Moris, Philip A. Jinks
-
Publication number: 20030103907Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.Type: ApplicationFiled: August 8, 2002Publication date: June 5, 2003Inventors: Robert K. Schultz, David W. Schultz, Martin J. Oliver, Robert A. Moris, Philip A. Jinks
-
Patent number: 6346232Abstract: Pharmaceutical solution aerosol formulations comprising beclomethasone 17,21 dipropionate, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.Type: GrantFiled: March 29, 2000Date of Patent: February 12, 2002Assignee: 3M Innovative Properties CompanyInventors: Robert K. Schultz, David W. Schultz
-
Patent number: 5980867Abstract: Pharmaceutical aerosol formulations comprising flunisolide, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.Type: GrantFiled: July 6, 1998Date of Patent: November 9, 1999Assignee: 3M Innovative Prperties CompanyInventors: Tsi-Zong Tzou, Robert K. Schultz, Danna L. Ross
-
Patent number: 5899201Abstract: A hand held aerosol actuator involving an aerosol source and a chamber having walls defining a constriction aperture. The aerosol source communicates with the chamber and directs an aerosol dose along an axis into the chamber. The constriction aperture is coaxial with the exit orifice and is dimensioned such that the respirable mass of the aerosol dose is increased relative to the respirable mass of an aerosol dose expelled through a like actuator not having the constriction aperture.Type: GrantFiled: May 26, 1993Date of Patent: May 4, 1999Assignee: Minnesota Mining and Manufacturing CompanyInventors: Robert K. Schultz, Constantinos Sioutas
-
Patent number: 5776432Abstract: Pharmaceutical solution aerosol formulations comprising beclomethasone 17,21 dipropionate, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.Type: GrantFiled: May 31, 1995Date of Patent: July 7, 1998Assignee: Minnesota Mining and Manufacturing CompanyInventors: Robert K. Schultz, David W. Schultz
-
Patent number: 5776433Abstract: Pharmaceutical aerosol formulations substantially free of chlorofluorocarbons and comprising a therapeutically effective amount of flunisolide in solution with ethanol and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof are used for the treatment of bronchial asthma. The formulation may be delivered by a metered dose inhaler with a canister that is inert to flunisolide.Type: GrantFiled: May 31, 1995Date of Patent: July 7, 1998Assignee: Minnesota Mining and Manufacturing CompanyInventors: Tsi-Zong Tzou, Robert K. Schultz, Danna L. Ross
-
Patent number: 5674592Abstract: Low energy surfaces based on nanostructured films exhibit advancing and receding contact angles for liquids such that (1) the difference between the advancing and receding contact angles approaches zero and (2) the advancing and receding contact angles approach 180.degree.. The low energy surface of the present invention comprises a nanostructured film coated with an organized molecular assembly (OMA). Advantageously, the chemical and wetting characteristics of the surface can be altered by changing the functionality of the OMA end groups exposed to the environment in contact with the surface of the nanostructured film.Type: GrantFiled: May 4, 1995Date of Patent: October 7, 1997Assignee: Minnesota Mining and Manufacturing CompanyInventors: John C. Clark, Mark K. Debe, Harry E. Johnson, Danna L. Ross, Robert K. Schultz